<html>
<head><title>
Prepared and filed by St Ives Financial
</title>
</head>
<body bgcolor="#FFFFFF">
<page>
<p align="center"><font size="2" face="serif"><b>UNITED STATES<br>
</b></font><font size="2" face="serif"><b>SECURITIES AND EXCHANGE COMMISSION<br>
</b></font><font size="2" face="serif"><b>Washington, D. C.  20549</b></font></p>
<p align="center"><font size="2" face="serif"><b>___________</b></font></p>
<p align="center"><font size="2" face="serif"><b>FORM 8-K</b></font></p>
<p align="center"><font size="2" face="serif"><b>CURRENT REPORT</b></font></p>
<p align="center"><font size="2" face="serif"><b>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></font></p>
<p align="center"><font size="2" face="serif"><b>June 15, 2006<br>
</b></font><font size="2" face="serif">Date of report (Date of earliest event reported)</font></p>
<p align="center"><b><font face="serif" size="3">APPLERA CORPORATION<br>
</font></b><font size="2" face="serif">(Exact name of registrant as specified in its charter)</font></p>
<table align="center" width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td width="33%" align="center"><font size="2" face="serif"><b>Delaware</b><br>
  (State or other jurisdiction<br>
  of Incorporation)</font></td>
<td width="34%" align="center"><font size="2" face="serif"><b>1-4389</b><br>
(Commission<br>
file
number)</font></td>
<td align="center"><font size="2" face="serif"><b>06-1534213</b><br>
(IRS Employer<br>
Identification No.)</font></td>
</tr>
</table>
<p align="center"><font size="2" face="serif"><b>301 Merritt 7<br>
</b></font><font size="2" face="serif"><b>Norwalk, Connecticut  06851<br>
</b></font><font size="2" face="serif">(Address of Principal Executive Offices, Including Zip Code)</font></p>
<p align="center"><font size="2" face="serif"><b>(203) 840-2000<br>
</b></font><font size="2" face="serif">(Registrant&#8217;s
telephone number, including area code)</font></p>
<p align="center"><font size="2" face="serif"><b>N/A<br></b>(Former name or former address, if changed since last report)<br></font></p>
<p align="left"><font size="2" face="serif">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></p>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td width="3%"><img src="emptybox.gif" width="12" height="12"></td>
<td align="left"><font size="2" face="serif">Written communications pursuant
    to Rule 425 under the Securities Act (17 CFR 230.425)</font></td>
</tr>
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td><font size="2" face="serif"><img src="emptybox.gif" width="12" height="12"></font></td>
<td align="left"><font size="2" face="serif">Soliciting material pursuant to
    Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></td>
</tr>
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td><font size="2" face="serif"><img src="emptybox.gif" width="12" height="12"></font></td>
<td align="left"><font size="2" face="serif">Pre-commencement communications
    pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></td>

</tr>
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td><font size="2" face="serif"><img src="emptybox.gif" width="12" height="12">&nbsp;</font></td>
<td align="left"><font size="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font> </td>
</tr>
</table>
<p align="center">&nbsp;</p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>
<a name="p?"></a>
<p align="left"><font size="2" face="serif"><b>Item 1.01.&nbsp;&nbsp;&nbsp;Entry into a Material
Definitive Agreement.</b></font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<i><u>Grants of Restricted Stock Units</u>.  </i>At a meeting of the Management Resources Committee (the &#8220;MRC&#8221;) of the Board of Directors of Applera Corporation (the &#8220;Company&#8221;) held on June 15, 2006, the MRC approved the grant of restricted stock units (&#8220;RSUs&#8221;) relating to shares of Applera Corporation &#150; Celera Genomics Group Common Stock (&#8220;Celera Genomics Stock&#8221;) to some employees of the Company and its subsidiaries pursuant to the Applera Corporation/Celera Genomics Group Amended and Restated 1999 Stock Incentive Plan.  The action of the MRC included grants of the following number of RSUs to the following
executive officers of the Company:</font></p>
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td width="45%"><font size="2" face="serif"><u>Executive Officer</u></font></td>
    <td colspan="2" align="center"><font size="2" face="serif"><u>Number of RSUs</u>&nbsp;</font></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td colspan="2" align="center">&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="serif">Tony L. White&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br>
    </font><font size="2" face="serif">Chairman, President<br>
    </font><font size="2" face="serif">and Chief Executive Officer</font></td>
    <td colspan="2" align="center" valign="top"><font size="2" face="serif">38,400</font></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td width="7%">&nbsp;</td>
    <td width="7%">&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="serif">Barbara J. Kerr<br>
    </font><font size="2" face="serif">Vice President, Human Resources</font></td>
    <td colspan="2" align="center" valign="top"><font size="2" face="serif">10,800</font></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="serif">Kathy P. Ordo&#241;ez<br>
    </font><font size="2" face="serif">Senior Vice President and President, Celera<br>
    </font><font size="2" face="serif">Genomics Group</font></td>
    <td colspan="2" align="center" valign="top"><font size="2" face="serif">90,000</font></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td align="left"><font size="2" face="serif">William B. Sawch<br>
    Senior Vice President and General Counsel</font></td>
    <td colspan="2" align="center" valign="top"><font size="2" face="serif">13,200</font></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="serif">Dennis L. Winger<br>
    Senior Vice President and<br>
    Chief Financial Officer</font></td>
    <td colspan="2" align="center" valign="top"><font size="2" face="serif">13,200</font></td>
    <td>&nbsp;</td>
  </tr>
</table>

<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each RSU represents the right to receive one share of Celera Genomics Stock at the time the RSU vests.  The RSUs granted to the Company&#8217;s executive officers generally vest in four increments as follows:</font></p>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td width="3%"></td>
<td width="3%">
<font size="2" face="serif">&#149;</font></td>
<td>
<font size="2" face="serif">an increment of up to 16.67% of the total amount following the end of fiscal year 2007, based on the attainment of revenue objectives for the Celera Genomics Group established by the MRC for that year;</font></td>
</tr>
<tr>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td width="3%"></td>
<td width="3%">
<font size="2" face="serif">&#149;</font></td>
<td>
<font size="2" face="serif">an increment of up to 16.67% of the total amount following the end of fiscal year 2008 based on the attainment of revenue objectives for the Celera Genomics Group established by the MRC for that year;</font></td>
</tr>
<tr>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
</table>
<p align="center"><font size="2" face="serif"></font></p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page> <a name="p?"></a>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td width="3%"></td>
<td width="3%">
<font size="2" face="serif">&#149;</font></td>
<td>
<font size="2" face="serif">an increment of up to 16.67% of the total amount
following the end of fiscal year 2009 based on the attainment of revenue objectives
for the Celera Genomics Group established by the MRC for that year; and</font></td>
</tr>
<tr>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td width="3%"></td>
<td width="3%">
<font size="2" face="serif">&#149;</font></td>
<td>
<font size="2" face="serif">an increment of up to 50% of the total amount following the end of fiscal year 2009 based on the attainment of profitability objectives for the Celera Genomics Group established by the MRC for fiscal years 2008 and 2009.  </font></td>
</tr>
</table>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
    RSUs as to which the vesting targets have not been attained will be forfeited.
    RSUs that have not vested will be forfeited and revert back to the Company
    upon termination of employment with the Company or a subsidiary for any reason,
    although the MRC has the discretion to modify the vesting requirements based
    on individual circumstances. <b><i></i></b>Prior to the vesting of the RSUs,
    the recipient will not be deemed to be the holder of, or have any of the
    rights of a holder with respect to, any shares of Celera Genomics Stock deliverable
    with respect to the RSUs. </font></p>
<p align="center">&nbsp;</p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>
<a name="p?"></a>
<p align="center"><font size="2" face="serif"><b>SIGNATURES</b></font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>           </b></font></p>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td>&nbsp;</td>
  <td colspan="2"><font size="2" face="serif"><b>APPLERA CORPORATION</b></font></td>
  </tr>
<tr valign="top">
  <td>&nbsp;</td>
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="50%"><font size="2" face="serif">&nbsp;</font></td>
<td width="3%"><font size="2" face="serif">By: </font></td>
<td align="left">
<font size="2" face="serif"> <u>/s/ Dennis L. Winger&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></font></td>
</tr>
<tr valign="top">
<td><font size="2" face="serif">&nbsp;</font></td>
<td><font size="2" face="serif">&nbsp;</font></td>
<td align="left"><font size="2" face="serif">Dennis L. Winger</font></td>
</tr>
<tr valign="top">
<td><font size="2" face="serif">&nbsp;</font></td>
<td><font size="2" face="serif">&nbsp;</font></td>
<td align="left"><font size="2" face="serif">Senior Vice President and</font></td>
</tr>
<tr valign="top">
<td><font size="2" face="serif">&nbsp;</font></td>
<td><font size="2" face="serif">&nbsp;</font></td>
<td align="left"><font size="2" face="serif">Chief Financial Officer</font></td>
</tr>
</table>
<p align="left"><font size="2" face="serif">Dated:  June 21, 2006</font></p>
<p align="center">&nbsp;</p>
<hr noshade align="center" width="100%" size="2">
</body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "b413766_8k.htm", "description": "FORM 8K", "secsgml_size_bytes": 12143}]
{"company-data": {"conformed-name": "APPLERA CORP", "cik": "0000077551", "assigned-sic": "3826", "irs-number": "061534213", "state-of-incorporation": "DE", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-04389", "film-number": "06917819"}, "business-address": {"street1": "301 MERRITT 7", "city": "NORWALK", "state": "CT", "zip": "06851", "phone": "2038402000"}, "mail-address": {"street1": "301 MERRITT 7", "city": "NORWALK", "state": "CT", "zip": "06851"}, "former-company": [{"former-conformed-name": "PE CORP", "date-changed": "19990129"}, {"former-conformed-name": "PERKIN ELMER CORP", "date-changed": "19930601"}]}
Prepared and filed by St Ives Financial
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C.  20549
___________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
June 15, 2006
Date of report (Date of earliest event reported)
APPLERA CORPORATION
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction
of Incorporation)
1-4389
(Commission
file
number)
06-1534213
(IRS Employer
Identification No.)
301 Merritt 7
Norwalk, Connecticut  06851
(Address of Principal Executive Offices, Including Zip Code)
(203) 840-2000
(Registrant's
telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant
    to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to
    Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications
    pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01.   Entry into a Material
Definitive Agreement.
Grants of Restricted Stock Units
.
At a meeting of the Management Resources Committee (the "MRC") of the Board of Directors of Applera Corporation (the "Company") held on June 15, 2006, the MRC approved the grant of restricted stock units ("RSUs") relating to shares of Applera Corporation – Celera Genomics Group Common Stock ("Celera Genomics Stock") to some employees of the Company and its subsidiaries pursuant to the Applera Corporation/Celera Genomics Group Amended and Restated 1999 Stock Incentive Plan.  The action of the MRC included grants of the following number of RSUs to the following
executive officers of the Company:
Executive Officer
Number of RSUs
Tony L. White
Chairman, President
and Chief Executive Officer
38,400
Barbara J. Kerr
Vice President, Human Resources
10,800
Kathy P. Ordoñez
Senior Vice President and President, Celera
Genomics Group
90,000
William B. Sawch
Senior Vice President and General Counsel
13,200
Dennis L. Winger
Senior Vice President and
Chief Financial Officer
13,200
Each RSU represents the right to receive one share of Celera Genomics Stock at the time the RSU vests.  The RSUs granted to the Company's executive officers generally vest in four increments as follows:
•
an increment of up to 16.67% of the total amount following the end of fiscal year 2007, based on the attainment of revenue objectives for the Celera Genomics Group established by the MRC for that year;
•
an increment of up to 16.67% of the total amount following the end of fiscal year 2008 based on the attainment of revenue objectives for the Celera Genomics Group established by the MRC for that year;
•
an increment of up to 16.67% of the total amount
following the end of fiscal year 2009 based on the attainment of revenue objectives
for the Celera Genomics Group established by the MRC for that year; and
•
an increment of up to 50% of the total amount following the end of fiscal year 2009 based on the attainment of profitability objectives for the Celera Genomics Group established by the MRC for fiscal years 2008 and 2009.
Any
    RSUs as to which the vesting targets have not been attained will be forfeited.
    RSUs that have not vested will be forfeited and revert back to the Company
    upon termination of employment with the Company or a subsidiary for any reason,
    although the MRC has the discretion to modify the vesting requirements based
    on individual circumstances.
Prior to the vesting of the RSUs,
    the recipient will not be deemed to be the holder of, or have any of the
    rights of a holder with respect to, any shares of Celera Genomics Stock deliverable
    with respect to the RSUs.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
APPLERA CORPORATION
By:
/s/ Dennis L. Winger
Dennis L. Winger
Senior Vice President and
Chief Financial Officer
Dated:  June 21, 2006